JP6257596B2 - ピラゾール誘導体およびｌｐａｒ５アンタゴニストとしてのその使用 - Google Patents
ピラゾール誘導体およびｌｐａｒ５アンタゴニストとしてのその使用 Download PDFInfo
- Publication number
- JP6257596B2 JP6257596B2 JP2015512072A JP2015512072A JP6257596B2 JP 6257596 B2 JP6257596 B2 JP 6257596B2 JP 2015512072 A JP2015512072 A JP 2015512072A JP 2015512072 A JP2015512072 A JP 2015512072A JP 6257596 B2 JP6257596 B2 JP 6257596B2
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- series consisting
- cycloalkyl
- unsubstituted
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 CC(CC(C(O*)=O)=NOC)=O Chemical compound CC(CC(C(O*)=O)=NOC)=O 0.000 description 2
- ALCUPGQAVZDLII-UHFFFAOYSA-N CC(C(Nc(cc1)ccc1C(O)=O)=O)OCc(c(C)c1-c2ccc(C(F)(F)F)cc2)n[n]1-c(cc1)ccc1Cl Chemical compound CC(C(Nc(cc1)ccc1C(O)=O)=O)OCc(c(C)c1-c2ccc(C(F)(F)F)cc2)n[n]1-c(cc1)ccc1Cl ALCUPGQAVZDLII-UHFFFAOYSA-N 0.000 description 1
- DYFZSMCIWRJDNT-UHFFFAOYSA-N CC(C(Nc(cc1)ccc1C(O)=O)=O)OCc1c[n](-c2ccccc2)nc1-c1cc(cccc2)c2cc1 Chemical compound CC(C(Nc(cc1)ccc1C(O)=O)=O)OCc1c[n](-c2ccccc2)nc1-c1cc(cccc2)c2cc1 DYFZSMCIWRJDNT-UHFFFAOYSA-N 0.000 description 1
- IIUYCDJVRPBYSE-UHFFFAOYSA-N CC(C)C(C(Nc(cc1)ccc1C(O)=O)=O)OCc(c(C)c1-c2ccc(C)cc2)n[n]1-c(c(Cl)c1)ccc1Cl Chemical compound CC(C)C(C(Nc(cc1)ccc1C(O)=O)=O)OCc(c(C)c1-c2ccc(C)cc2)n[n]1-c(c(Cl)c1)ccc1Cl IIUYCDJVRPBYSE-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12305552.7 | 2012-05-18 | ||
| EP12305552 | 2012-05-18 | ||
| PCT/EP2013/060171 WO2013171317A1 (en) | 2012-05-18 | 2013-05-16 | Pyrazole derivatives and their use as lpar5 antagonists |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015517514A JP2015517514A (ja) | 2015-06-22 |
| JP2015517514A5 JP2015517514A5 (https=) | 2016-06-23 |
| JP6257596B2 true JP6257596B2 (ja) | 2018-01-10 |
Family
ID=48446368
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015512072A Expired - Fee Related JP6257596B2 (ja) | 2012-05-18 | 2013-05-16 | ピラゾール誘導体およびｌｐａｒ５アンタゴニストとしてのその使用 |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US9346762B2 (https=) |
| EP (1) | EP2882715B1 (https=) |
| JP (1) | JP6257596B2 (https=) |
| KR (1) | KR20150010973A (https=) |
| CN (1) | CN104302625B (https=) |
| AU (1) | AU2013261718B2 (https=) |
| BR (1) | BR112014028406A2 (https=) |
| CA (1) | CA2871542A1 (https=) |
| CY (1) | CY1118618T1 (https=) |
| DK (1) | DK2882715T3 (https=) |
| ES (1) | ES2612205T3 (https=) |
| HR (1) | HRP20170098T1 (https=) |
| HU (1) | HUE032890T2 (https=) |
| IL (1) | IL235221A (https=) |
| LT (1) | LT2882715T (https=) |
| MX (1) | MX347615B (https=) |
| PL (1) | PL2882715T3 (https=) |
| PT (1) | PT2882715T (https=) |
| RU (1) | RU2645344C2 (https=) |
| SG (1) | SG11201407210SA (https=) |
| SI (1) | SI2882715T1 (https=) |
| WO (1) | WO2013171317A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2850062B1 (en) | 2012-05-18 | 2017-07-19 | Sanofi | Pyridine derivatives and their use in the treatment of conditions associated with pathological thrombus formation |
| BR112017026535B1 (pt) | 2015-06-12 | 2023-12-19 | Vettore, LLC | Composto e composição farmacêutica |
| WO2018111904A1 (en) | 2016-12-12 | 2018-06-21 | Vettore, LLC | Heterocyclic inhibitors of mct4 |
| PL4038052T3 (pl) | 2019-10-02 | 2024-08-26 | Domain Therapeutics | Antagoniści receptora ep4 prostaglandyny e2 (pge2) |
| WO2024092205A1 (en) * | 2022-10-27 | 2024-05-02 | The Trustees Of Indiana University | Inhibition of ship1 as a therapeutic strategy for the treatment of alzheimer's disease |
| CN119930520B (zh) * | 2023-11-03 | 2026-03-06 | 中国药科大学 | N-芳基吡唑类化合物及其药物组合物和应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1230441B (it) | 1989-02-07 | 1991-10-23 | Acraf | Eteri della serie dell'indazolo |
| US7279478B2 (en) | 2002-09-04 | 2007-10-09 | Merck Frosst Canada & Co. | Cathepsin cysteine protease inhibitors |
| EP2118066A1 (en) | 2007-02-09 | 2009-11-18 | Takeda Pharmaceutical Company Limited | Fused ring compounds as partial agonists of ppar-gamma |
| WO2009080227A2 (en) | 2007-12-26 | 2009-07-02 | Sanofi-Aventis | Pyrazole-carboxamide derivatives as p2y12 antagonists |
| JP5509100B2 (ja) | 2008-03-07 | 2014-06-04 | アジェンデ・キミケ・リウニテ・アンジェリニ・フランチェスコ・ア・チ・エレ・ア・エフェ・ソシエタ・ペル・アチオニ | 新規な１−ベンジル−３−ヒドロキシメチルインダゾール誘導体及びそのＭＣＰ−１，ＣＸ３ＣＲ１及びｐ４０の発現に基づく疾病の治療への使用 |
| EA019711B1 (ru) * | 2008-03-07 | 2014-05-30 | Ацьенде Кимике Рьюните Анджелини Франческо A.K.P.A.Ф. С.П.А. | ПРОИЗВОДНЫЕ 1-БЕНЗИЛ-3-ГИДРОКСИМЕТИЛИНДАЗОЛА, СОДЕРЖАЩАЯ ИХ ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И ИХ ПРИМЕНЕНИЕ ПРИ ЛЕЧЕНИИ ЗАБОЛЕВАНИЙ, ОБУСЛОВЛЕННЫХ ЭКСПРЕССИЕЙ МСР-1, СХ3CR1 ИЛИ р40 |
| KR20110128942A (ko) * | 2009-03-19 | 2011-11-30 | 사노피 | Ｈｓｐ９０ 억제 인다졸 유도체, 그를 함유하는 조성물 및 그의 용도 |
| GEP20135879B (en) | 2009-08-03 | 2013-07-10 | Aziende Chimiche Riunite Angelini Francesco A C R A F S P A It | Method of 1-benzyl-3-hydroxymethyl-1h-indazole preparation, derivatives thereof, and required magnesium intermediates |
| ES2530345T3 (es) * | 2010-09-02 | 2015-03-02 | Merck Patent Gmbh | Derivados de pirazolopiridinona como antagonistas del receptor del LPA |
| EP2850062B1 (en) | 2012-05-18 | 2017-07-19 | Sanofi | Pyridine derivatives and their use in the treatment of conditions associated with pathological thrombus formation |
-
2013
- 2013-05-16 US US14/401,050 patent/US9346762B2/en not_active Expired - Fee Related
- 2013-05-16 PL PL13723151T patent/PL2882715T3/pl unknown
- 2013-05-16 HU HUE13723151A patent/HUE032890T2/hu unknown
- 2013-05-16 WO PCT/EP2013/060171 patent/WO2013171317A1/en not_active Ceased
- 2013-05-16 DK DK13723151.0T patent/DK2882715T3/en active
- 2013-05-16 CN CN201380025967.9A patent/CN104302625B/zh not_active Expired - Fee Related
- 2013-05-16 CA CA2871542A patent/CA2871542A1/en not_active Abandoned
- 2013-05-16 JP JP2015512072A patent/JP6257596B2/ja not_active Expired - Fee Related
- 2013-05-16 BR BR112014028406A patent/BR112014028406A2/pt not_active Application Discontinuation
- 2013-05-16 HR HRP20170098TT patent/HRP20170098T1/hr unknown
- 2013-05-16 AU AU2013261718A patent/AU2013261718B2/en not_active Ceased
- 2013-05-16 PT PT137231510T patent/PT2882715T/pt unknown
- 2013-05-16 MX MX2014014011A patent/MX347615B/es active IP Right Grant
- 2013-05-16 EP EP13723151.0A patent/EP2882715B1/en not_active Not-in-force
- 2013-05-16 SG SG11201407210SA patent/SG11201407210SA/en unknown
- 2013-05-16 SI SI201330499A patent/SI2882715T1/sl unknown
- 2013-05-16 LT LTEP13723151.0T patent/LT2882715T/lt unknown
- 2013-05-16 KR KR20147033843A patent/KR20150010973A/ko not_active Ceased
- 2013-05-16 ES ES13723151.0T patent/ES2612205T3/es active Active
- 2013-05-16 RU RU2014151360A patent/RU2645344C2/ru not_active IP Right Cessation
-
2014
- 2014-10-20 IL IL235221A patent/IL235221A/en active IP Right Grant
-
2017
- 2017-02-08 CY CY20171100175T patent/CY1118618T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SI2882715T1 (sl) | 2017-03-31 |
| EP2882715A1 (en) | 2015-06-17 |
| SG11201407210SA (en) | 2014-12-30 |
| US9346762B2 (en) | 2016-05-24 |
| DK2882715T3 (en) | 2017-02-13 |
| CA2871542A1 (en) | 2013-11-21 |
| AU2013261718A1 (en) | 2014-12-18 |
| KR20150010973A (ko) | 2015-01-29 |
| RU2014151360A (ru) | 2016-07-10 |
| CN104302625B (zh) | 2017-04-19 |
| US20150141477A1 (en) | 2015-05-21 |
| CN104302625A (zh) | 2015-01-21 |
| PL2882715T3 (pl) | 2017-04-28 |
| CY1118618T1 (el) | 2017-07-12 |
| MX2014014011A (es) | 2015-02-12 |
| HUE032890T2 (hu) | 2017-11-28 |
| IL235221A (en) | 2016-06-30 |
| BR112014028406A2 (pt) | 2017-06-27 |
| WO2013171317A1 (en) | 2013-11-21 |
| JP2015517514A (ja) | 2015-06-22 |
| ES2612205T3 (es) | 2017-05-12 |
| RU2645344C2 (ru) | 2018-02-21 |
| LT2882715T (lt) | 2017-02-10 |
| PT2882715T (pt) | 2016-12-30 |
| EP2882715B1 (en) | 2016-11-09 |
| HRP20170098T1 (hr) | 2017-03-24 |
| MX347615B (es) | 2017-05-04 |
| AU2013261718B2 (en) | 2017-10-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6257596B2 (ja) | ピラゾール誘導体およびｌｐａｒ５アンタゴニストとしてのその使用 | |
| KR101589332B1 (ko) | ２ｈ-크로멘 화합물 및 그의 유도체 | |
| EP2066641B1 (en) | Pyrazole derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto | |
| JP5309033B2 (ja) | ヘテロアリールシクロプロパンカルボキサミド及び薬剤としてのその使用 | |
| KR20150130415A (ko) | 질환의 치료에 유용한 헤테로환식 화합물 | |
| WO2005019218A1 (ja) | ピロロピリミジンチオン誘導体 | |
| CZ297544B6 (cs) | Substituované N-[(aminoiminomethyl)-fenyl]propylamidy nebo N-[(aminomethyl)fenyl]propylamidy | |
| JP2015521183A (ja) | ピリジン誘導体および病理学的血栓形成に関連する状態の治療へのその使用 | |
| KR20210084581A (ko) | 치료 화합물 및 조성물 | |
| JP2009184925A (ja) | ５−（１ｈ−１，２，３−トリアゾール−４−イル）−１ｈ−ピラゾール誘導体 | |
| JP6238970B2 (ja) | ベンゾ［１，３］ジオキシン誘導体およびｌｐａｒ５アンタゴニストとしてのその使用 | |
| US5753667A (en) | 1-oxo-2- (phenylsulphonylamino) pentylpiperidine derivatives, their preparation and their therapeutic application | |
| JP2021528456A (ja) | Ａｓｋ１阻害剤 | |
| KR20200118088A (ko) | 치료 화합물 및 조성물 | |
| CN117164566B (zh) | 一种氧代哒嗪类化合物及其制备方法和用途 | |
| JP2007262022A (ja) | 新規２−チオフェンカルボキサミド誘導体 | |
| CN116194439B (zh) | Soce抑制剂及其治疗用途 | |
| HK40035558A (en) | Aromatic sulfonamide derivatives for the treatment of ischemic stroke |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160428 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20160428 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20170131 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170228 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20170526 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170728 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20171107 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20171205 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6257596 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| LAPS | Cancellation because of no payment of annual fees |